

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Chris Kornak at 240–627–3705 or [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov). Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

**SUPPLEMENTARY INFORMATION:** Technology description follows:

#### Humanized Murine Monoclonal Antibodies That Neutralize Type-1 Interferon (IFN) Activity

##### Description of Technology

Interferons (IFNs) are a family of cytokines that function in response to an immune challenge such as a viral or bacterial infection. Type I IFNs are produced by immune cells (predominantly monocytes and dendritic cells) as well as fibroblasts and signal through a specific cell surface receptor complex (IFNAR) that consist of IFNAR1 and IFNAR2 chains. Type-I IFNs exert several common effects including antiviral, antiproliferative, and immunomodulatory activities. However, Type I IFNs also have pro-inflammatory effects, especially in the presence of TNF- $\alpha$ . Therefore, neutralizing the pro-inflammatory effect of Type I interferon could have wide clinical applications in autoimmune diseases like SLE, or in acute and chronic viral diseases like SARS-CoV-2, HIV or HCV infection, respectively, in which IFN-induced inflammation may be detrimental.

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID)

have developed two anti-IFN receptor 2 (IFNAR2) antibodies, B7 and A10, that are effective *in vitro* at neutralizing Type I IFN activities. The antibodies are comprised of two heavy chains and two light chains of amino acids. Both antibodies are able to bind to the extracellular domain of IFNAR2, Type I IFN receptor subunit 2, thus suppressing IFN signaling.

Because there are no potent IFNAR2 antibodies for therapies commercially available at this time, these antibodies are a novel therapeutic tool that could be used exclusively or in combination to treat chronic inflammatory diseases (like autoimmune disorders such as SLE) in which sustained IFN production may lead to both systemic and specific organ dysfunctions or chronic viral diseases (such as HIV, HCV) in which sustained IFN production has deleterious effects on immunologic function.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

##### Potential Commercial Applications

Therapeutics for the treatment of chronic inflammatory conditions:

- In chronic inflammatory diseases (*e.g.*, autoimmune disorders such as SLE).
- In chronic viral diseases (such as HIV, HCV infection).
- In acute viral or inflammatory diseases (*e.g.*, SARS-CoV-2).

##### Development Stage

- Pre-clinical.

**Inventors:** Paolo Lusso, M.D. Ph.D., Hana Schmeisser, Ph.D., Kathryn C. Zoon, Ph.D., Qingbo, Liu, Ph.D., all of NIAID.

##### Publications:

- A.N. Morrow, H. Schmeisser, T. Tsuno, K.C. Zoon. A novel role for IFN-stimulated gene factor 3II in IFN- $\gamma$  induction of antiviral activity in human cells. *J Immunol* 186: 1685–93, 2011.
- C.A. Balinsky, H. Schmeisser, S. Ganesan, K. Singh, T.C. Pierson, K.C. Zoon. Nucleolin interacts with the dengue virus capsid protein and plays a role in formation of infectious virus particles. *J Virol* 87: 13094–106, 2013.
- H. Schmeisser, S.B. Fey, J. Horowitz, E.R. Fischer, C.A. Balinsky, K. Miyake, J. Bekisz, A.L. Snow, K.C. Zoon. Type I interferons induce autophagy in certain human cancer cell lines. *Autophagy* 9: 683–96, 2013.
- L.A. Zaritsky, J.R. Bedsaul, K.C. Zoon. Virus multiplicity of infection affects type I interferon subtype induction profiles and interferon-stimulated genes. *J Virol* 89 (22): 11534–48, 2015.

C.A. Balinsky, H. Schmeisser, A.I. Wells, S. Ganesan, T. Jin, K. Singh, K.C. Zoon. IRAV (FLJ112886), an interferon stimulated gene with antiviral activity against Dengue Virus, interacts with MOV 10. *J Virol* 14: 91(5), e01606–16, 2017.

A.W.T. Chiang, S. Li, B.P. Kellman, G. Chattopadhyay, Y. Zhang, Ch. Ch. Kuo, J.M. Gutierrez, F. Ghazi, H. Schmeisser, P. Ménard, S.P. Bjørn, B.G. Voldborg, A.S. Rosenberg, M. Puig, Nathan E. Lewis. Combating viral contaminants in CHO cells by engineering innate immunity. *Sci Rep* 9 (1), 8827, 2019.

**Intellectual Property:** HHS Reference No. E–220–2020–0; U.S. provisional application No. 63/094,572 filed on 10/21/2020 and PCT application PCT/US2021/056067.

**Licensing Contact:** To license this technology, please contact Chris Kornak 240–627–3705 or [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov), and reference E–220–2020.

**Collaborative Research Opportunity:** The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Chris Kornak at 240–627–3705 or [chris.kornak@nih.gov](mailto:chris.kornak@nih.gov).

Dated: April 8, 2022.

#### Surekha Vathyam,

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2022–07892 Filed 4–12–22; 8:45 am]

BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Development of Diagnostic for Imaging and Early Detection of Pancreatic Cancer and Pre-Cancerous Lesions by Targeting the Cholecystokinin-B Receptor

**AGENCY:** National Institutes of Health.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable, patent license to Georgetown University “Georgetown”, a private university located in Washington DC, to its rights to the invention embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before April 28, 2022 will be considered.

**ADDRESSES:** Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Whitney Hastings, Ph.D., Senior Technology Transfer Manager at [whitney.hastings2@nih.gov](mailto:whitney.hastings2@nih.gov).

**SUPPLEMENTARY INFORMATION:**

**Intellectual Property**

United States Provisional Patent Application No. 63/030,815, filed May 27, 2020, entitled "TARGETING THE CHOLECYSTOKININ-B RECEPTOR FOR IMAGING AND EARLY DETECTION OF PANCREATIC CANCER AND PRE-CANCEROUS LESIONS," [HHS Ref. No. E-184-2020-0].

The patent rights in these inventions have been assigned to the Government of the United States of America and Georgetown University. The prospective patent license will be for the purpose of consolidating the patent rights to Georgetown, the co-owner of said rights, for commercial development and marketing. Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35 U.S.C. 200-212.

The prospective patent license will be worldwide, exclusive, and may be limited to those fields of use commensurate in scope with the patent rights. It will be sublicensable, and any sublicenses granted by Georgetown will be subject to the provisions of 37 CFR part 401 and 404.

This technology discloses a method of detecting the presence of a pancreatic intraepithelial neoplasia lesion *in vivo* via administering to the subject a construct, or a pharmaceutically acceptable salt thereof, wherein the construct is comprised of siRNA-polymer nanoparticle complex that selectively bind to cholecystokinin-B receptors. The nanoparticle can be conjugated with a fluorophore or radioactive molecule (e.g., technetium). In conjunction with an imaging device, the polyplex nanoparticle could be used to detect the presence of precancerous pancreatic intraepithelial neoplasia (PanIN) lesions.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless

within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 7, 2022.

**Richard U. Rodriguez,**

*Associate Director, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2022-07866 Filed 4-12-22; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants.

*Date:* May 13, 2022.

*Time:* 1:00 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Marisa Srivareerat, Ph.D., Scientific Review Officer, Scientific Review Branch, Office of Extramural Policy, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 435-1258, [marisa.srivareerat@nih.gov](mailto:marisa.srivareerat@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: April 7, 2022.

**Tyeshia M. Roberson-Curtis,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2022-07866 Filed 4-12-22; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HOMELAND SECURITY**

**Coast Guard**

[Docket No. USCG-2022-0160]

**National Merchant Marine Personnel Advisory Committee Meeting; May 2022 Teleconference**

**AGENCY:** U.S. Coast Guard, Department of Homeland Security.

**ACTION:** Notice of Federal advisory committee teleconference meeting.

**SUMMARY:** The National Merchant Marine Personnel Advisory Committee (Committee) will meet via teleconference to discuss issues relating to personnel in the United States Merchant Marine including the training, qualifications, certification, documentation, and fitness of mariners.

**DATES:**

*Meeting:* The National Merchant Marine Personnel Advisory Committee will meet by teleconference on Tuesday, May 3, 2022, from 10:00 a.m. until 4:30 p.m. (Eastern Daylight Time). The teleconference may adjourn early if the Committee has completed its business.

*Comments and supporting documentation:* To ensure your comments are received by Committee members before the teleconference, submit your written comments no later than April 19, 2022.

**ADDRESSES:** To join the teleconference or to request special accommodations, contact the individual listed in the **FOR FURTHER INFORMATION CONTACT** section no later than 1 p.m. on April 19, 2022, to obtain the needed information. The number of individuals on a teleconference line is limited and will